,drug,MOAs
122,COc1ccc2[nH]c(C(=O)c3ccccc3)cc2c1,microtubule inhibitor
179,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist
25,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,bacterial DNA gyrase inhibitor
89,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,angiotensin receptor antagonist
73,O=C(C=Cc1ccccc1)NC(NC(=S)Nc1cccc2cccnc12)C(Cl)(Cl)Cl,eukaryotic translation initiation factor inhibitor
104,C#C[C@]1(O)CCC2C3CCC4=Cc5oncc5C[C@]4(C)C3CC[C@@]21C,estrogen receptor antagonist|progesterone receptor agonist
27,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,EGFR inhibitor
21,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,dopamine receptor antagonist|serotonin receptor antagonist
171,CCC1C=CC=CC[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C=CC(=O)OC2[C@@H](C)C(CC1)OC1(CC[C@@H](C)C(C[C@H](C)O)O1)[C@@H]2C,ATP synthase inhibitor|ATPase inhibitor
188,CC(=O)NC1=NN(C(C)=O)C(C)(c2ccccc2)S1,kinesin-like spindle protein inhibitor
82,O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2C1=NO,glycogen synthase kinase inhibitor|lipoxygenase inhibitor
55,O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1,CHK inhibitor
181,CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,pyruvate ferredoxin oxidoreductase inhibitor
208,CC1=CC(=O)c2ccccc2C1=O,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor
187,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,androgen receptor agonist
22,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor
37,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor
207,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|src inhibitor
124,CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21,butyrylcholinesterase inhibitor|cholinergic receptor antagonist
149,Cc1cc(NC(=O)Nc2ccc(N(C)C)cc2)c2cc(F)cc(F)c2n1,orexin receptor antagonist
147,CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)OCc1ccccc1,calpain inhibitor
60,COC(=O)Nc1nc2ccc(S(=O)c3ccccc3)cc2[nH]1,anthelmintic agent
193,CC(C)(C)c1cc(C=C(C#N)C(N)=S)cc(C(C)(C)C)c1O,tyrosine kinase inhibitor
107,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,lanosterol demethylase inhibitor|sterol demethylase inhibitor
9,CN1CCc2c(c3ccccc3n2Cc2ccc(C(=O)NO)cc2)C1,HDAC inhibitor
134,C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1,IGF-1 inhibitor
144,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,angiotensin converting enzyme inhibitor
98,Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(C(=O)NO)c1,metalloproteinase inhibitor
111,C/C=C/C[C@@H](C)[C@@H](O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)N[C@H](C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,calcineurin inhibitor
64,COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,Aurora kinase inhibitor
61,CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(c3ccc(N(C)C)cc3)CC21C,glucocorticoid receptor antagonist|progesterone receptor antagonist
49,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,BCL inhibitor
163,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,sodium channel blocker
51,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,mTOR inhibitor|PI3K inhibitor
148,Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,bacterial antifolate
101,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,rho associated kinase inhibitor
167,CCCCNc1ccc(C(=O)OCCN(C)C)cc1,membrane integrity inhibitor
58,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,FLT3 inhibitor|KIT inhibitor|PKC inhibitor
158,CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)[C@H](O)C(=O)NO,peptidase inhibitor
130,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor
26,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,CDK inhibitor
2,Brc1ccc2c(c1)CN1CCCC1=N2,None
113,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor
165,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,norepinephrine reputake inhibitor
88,CC1CC(C)C(=O)C(C(O)CC2CC(=O)NC(=O)C2)C1,protein synthesis inhibitor
100,COCC(=O)NCC=Cc1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,EGFR inhibitor|protein tyrosine kinase inhibitor
184,Nc1c2c(nc3ccccc13)CCCC2,acetylcholinesterase inhibitor
6,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,HIV protease inhibitor
159,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor
112,Cc1cnc(C(=O)O)c[n+]1[O-],cholesterol inhibitor
41,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F,DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor
18,Nc1nc2ccc(Cl)cc2c2nc(-c3ccco3)nn12,adenosine receptor antagonist
1,O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12,PKA inhibitor
194,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor
68,CCC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1,mTOR inhibitor
127,NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1,TGF beta receptor inhibitor
13,O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O,IKK inhibitor|NFkB pathway inhibitor
95,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,bacterial cell wall synthesis inhibitor
4,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,DNA inhibitor
199,CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,GK0582 inhibitor
182,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,FLT3 inhibitor|JAK inhibitor
202,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor
97,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12,tachykinin antagonist
3,CCC(C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](CC=C(C)[C@@H](OC3C[C@H](OC)C(O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)C=CC=C3CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,benzodiazepine receptor agonist
133,O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1,ATM kinase inhibitor|ATR kinase inhibitor
43,CCN(CC)CCOC1CCC2(C)C(=CCC3C4CCC(=O)C4(C)CCC32)C1,oxidosqualene cyclase inhibitor
85,CN(C)Cc1ccc(-c2nc3cccc4c3n2CCNC4=O)cc1,PARP inhibitor
102,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,cytochrome P450 inhibitor|imidazoline receptor ligand
123,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,FLT3 inhibitor
136,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1,laxative
200,Cc1cc(I)ccc1Nc1c(C(=O)NOCC2CC2)cc(F)c(F)c1F,MAP kinase inhibitor|MEK inhibitor
39,CCCCCS(=O)(=O)CCCCCCCCCCn1c(-c2ccc(O)cc2)c(C)c2cc(O)ccc21,estrogen receptor antagonist
78,CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CC(=O)NO)CC(C)C,matrix metalloprotease inhibitor
69,c1ccc2c(Oc3nc(Nc4ccc(N5CCOCC5)cc4)c4ncn(C5CCCCC5)c4n3)cccc2c1,smoothened receptor agonist
201,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,JAK inhibitor
74,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1,dopamine uptake inhibitor
110,COc1cc(NC(C)CCCN)c2ncccc2c1,antimalarial agent|DNA inhibitor
57,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,estrogen receptor antagonist|selective estrogen receptor modulator (SERM)
15,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,insulin sensitizer|PPAR receptor agonist
33,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,RAF inhibitor
197,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,carnitine palmitoyltransferase inhibitor
87,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,KIT inhibitor|VEGFR inhibitor
42,C[C@@H]1CC[C@H]2[C@@H](C)C(OC(=O)CCC(=O)O)OC3O[C@]4(C)CC[C@@H]1[C@]32OO4,DNA synthesis inhibitor
67,C#C[C@]1(O)CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@@]21C,progesterone receptor agonist
93,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)NC1CC1,Aurora kinase inhibitor|JAK inhibitor
83,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator
115,CCOc1ccccc1-n1c(C(C)N2CCN(C(=O)COc3ccc(Cl)cc3)CC2)nc2ccccc2c1=O,ion channel antagonist
204,CN1CCCC(CC2c3ccccc3Sc3ccccc32)C1,acetylcholine receptor antagonist
71,O=C1C(SCCO)=C(SCCO)C(=O)c2ccccc21,CDC inhibitor
36,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,serotonin receptor agonist
160,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,serotonin receptor antagonist
116,O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21,EGFR inhibitor|PKC inhibitor
91,O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1,IKK inhibitor
90,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor
94,CC(C)(C)c1ccc(C=CC(=O)Nc2ccc3c(c2)OCCO3)cc1,TRPV antagonist
176,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,barbiturate antiepileptic|GABA receptor modulator
196,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C,biliverdin reductase A activator|G protein-coupled receptor agonist
180,COCCn1c2c([n+](Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O,survivin inhibitor
168,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor
48,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,VEGFR inhibitor
